Table 2.
Multivariable Analysis of Factors Associated With CSF Use Among Women With Breast Cancer Who Received Treatment With Any Adjuvant Chemotherapy
| Any CSF |
First-Cycle CSF |
|||
|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |
| Age at diagnosis, years | ||||
| 65-69 | Referent | Referent | ||
| 70-74 | 1.15 | 1.05 to 1.27* | 0.96 | 0.84 to 1.10 |
| 75-79 | 1.25 | 1.12 to 1.41* | 1.12 | 0.95 to 1.32 |
| ≥ 80 | 1.06 | 0.89 to 1.25 | 1.09 | 0.85 to 1.39 |
| Race | ||||
| White | Referent | Referent | ||
| Black | 0.80 | 0.67 to 0.95* | 0.97 | 0.75 to 1.24 |
| Hispanic | 0.68 | 0.48 to 0.96* | 0.68 | 0.38 to 1.23 |
| Missing or other | 1.03 | 0.82 to 1.29 | 1.04 | 0.78 to 1.38 |
| Residence | ||||
| Metropolitan | Referent | Referent | ||
| Nonmetropolitan | 0.71 | 0.60 to 0.84* | 0.80 | 0.63 to 1.02 |
| Marital status | ||||
| Married | Referent | Referent | ||
| Unmarried | 0.94 | 0.87 to 1.02 | 0.99 | 0.88 to 1.10 |
| Unknown | 1.04 | 0.82 to 1.33 | 1.16 | 0.82 to 1.63 |
| Socioeconomic status | ||||
| Lowest (first) quintile | Referent | Referent | ||
| Second quintile | 0.94 | 0.80 to 1.10 | 0.93 | 0.75 to 1.16 |
| Third quintile | 1.00 | 0.85 to 1.18 | 1.12 | 0.89 to 1.40 |
| Fourth quintile | 0.97 | 0.82 to 1.15 | 1.14 | 0.91 to 1.44 |
| Highest (fifth) quintile | 1.07 | 0.90 to 1.27 | 1.39 | 1.10 to 1.76* |
| Comorbidity score | ||||
| 0 | Referent | Referent | ||
| 1 | 0.92 | 0.82 to 1.03 | 0.98 | 0.83 to 1.16 |
| > 1 | 0.85 | 0.69 to 1.04* | 1.05 | 0.81 to 1.38 |
| Tumor stage | ||||
| I | Referent | Referent | ||
| II/III | 0.98 | 0.88 to 1.10 | 1.03 | 0.87 to 1.22 |
| Tumor grade | ||||
| High | Referent | Referent | ||
| Low | 0.93 | 0.85 to 1.01 | 1.05 | 0.93 to 1.20 |
| Unknown | 0.90 | 0.77 to 1.06 | 0.96 | 0.76 to 1.22 |
| Chemotherapy type | ||||
| Taxane + anthracycline | Referent | Referent | ||
| Anthracycline | 0.73 | 0.64 to 0.83* | 0.41 | 0.36 to 0.48* |
| Taxane | 0.19 | 0.15 to 0.23* | 0.17 | 0.13 to 0.24* |
| Other | 0.25 | 0.22 to 0.29* | 0.09 | 0.07 to 0.11* |
| Chemotherapy duration, weeks | ||||
| 1-13 | 0.69 | 0.61 to 0.77* | 1.19 | 1.00 to 1.42 |
| 14-26 | Referent | Referent | ||
| > 26 | 1.05 | 0.92 to 1.19 | 0.75 | 0.64 to 0.87* |
| Hormone-receptor status | ||||
| Negative | Referent | Referent | ||
| Positive | 1.00 | 0.90 to 1.11 | 1.04 | 0.91 to 1.19 |
| Oncologist training | ||||
| Non–United States | Referent | Referent | ||
| United States | 0.72 | 0.62 to 0.84* | 0.73 | 0.61 to 0.88* |
| Oncologist degree | ||||
| DO | Referent | Referent | ||
| MD | 1.30 | 0.95 to 1.79 | 0.97 | 0.60 to 1.55 |
| Specialty | ||||
| Nononcologist | Referent | Referent | ||
| Oncologist | 1.45 | 1.17 to 1.80* | 1.44 | 1.07 to 1.96* |
| Oncologist sex | ||||
| Male | Referent | Referent | ||
| Female | 1.00 | 0.85 to 1.18 | 0.99 | 0.81 to 1.21 |
| Oncologist year of graduation | ||||
| 1990s | Referent | Referent | ||
| 1980s | 0.92 | 0.75 to 1.13 | 1.16 | 0.92 to 1.47 |
| 1970s | 0.76 | 0.62 to 0.95* | 1.00 | 0.78 to 1.28 |
| 1960s | 0.79 | 0.62 to 1.01 | 0.85 | 0.61 to 1.16 |
| Oncologist practice setting | ||||
| Academic | Referent | Referent | ||
| Private practice | 1.06 | 0.91 to 1.24 | 1.14 | 0.94 to 1.38 |
| Volume | ||||
| 1-9 cases | Referent | Referent | ||
| ≥ 10 cases | 1.14 | 0.96 to 1.30 | 1.05 | 0.88 to 1.26 |
Abbreviations: CSF, colony-stimulating factor; DO, Doctor of Osteopathic Medicine; MD, Doctor of Medicine; OR, odds ratio.
*
P ≤ .05 (corrected for year of diagnosis).